
OpenAI forum explores how reasoning AI will shape global economics
At a forum hosted by OpenAI, speakers from the company and academia offered an in-depth look at the evolving landscape of artificial intelligence, tracing the shift from traditional pre-training models to a new generation of reasoning-based systems.
They also addressed the profound economic, political and organisational implications of these technologies.
Kicking off the session, Noam Brown, Member of Technical Staff at OpenAI, reflected on what distinguishes current models from past breakthroughs in AI. "There have been a lot of cool, impressive results in AI for a long time… but what's really special about ChatGPT and the AIs that we see today is the generality—the fact that they can do so many different things without being targeted at those things."
Brown detailed how early models were trained to predict the next word in a sequence using vast internet text data. "Somewhere in that internet is chess games… it has to understand chess… it has to understand how good these players are," he said. Similarly, to predict the end of a mystery novel, "it has to understand the characters, the motivations… a world model of how an axe can move through the air."
This "pre-training paradigm" formed the basis for models like GPT-2 and GPT-3. However, scaling this approach quickly becomes costly. "GPT-2 costs, I think, $5,000 to $50,000… GPT-4 costs around $50 million," Brown noted.
To address these limitations, OpenAI has begun exploring a second paradigm: reasoning. This involves investing more in inference—the thinking a model does when responding—rather than just training. "What if instead of just scaling the training cost, we scale up the amount of thinking that the model does before responding?" Brown asked. This idea underpins OpenAI's "O series" models.
"GPT-4… costs a penny to query. O1… it's going to think for maybe a minute… and it's going to cost a dollar," Brown explained. "But that response is going to be a lot better than the one that cost a penny."
Using benchmarks to demonstrate the shift, Brown showed that GPT-4 scored 13% on the American Mathematics Exam, while O1 preview reached 57%, and the full O1 model reached 83%. On competition coding, O1 reached the 89th percentile compared to GPT-4's 11th. OpenAI's O3 model, yet to be released at the time of the event, scored in the top 0.1% of all human competition coders.
Brown said this marked a meaningful shift. "I fully expect that by the end of this year our models will be superhuman at competition coding."
He cautioned against dismissing current models based on past performance. "A lot of what they're pointing to as flaws is things that were true six months ago but are no longer true today," he said, highlighting reasoning advances such as recognising that certain tasks are logically impossible.
OpenAI's Chief Economist Ronnie Chatterji spoke next, shifting the discussion to geopolitics. "The idea of how a more divided geopolitics, how great power competition… are shaping our current environment… is really first order at OpenAI."
He described how internal debate at OpenAI revolved around whether to frame AI development in terms of "democratic AI" versus "autocratic AI." While some supported the move, others raised concerns. "If we did so, we might both lose credibility in key markets… and we actually obviously might lose access to key talent."
Chatterji also addressed the merging of economics with national security: "Economics and national security are being blended in a lot of contexts… problems are coming at us and people are looping us into those discussions."
In group discussions, education emerged as a major theme. "How does students using AI in the classroom… affect how you do assessment?" one participant asked. Some compared the issue to calculators: "You gotta get really good at using a calculator."
Others focused on AI's role in the economy. One group proposed a "multidimensional task measure" combining economic value, task risk and complexity. Another explored the "last mile delivery" of services like healthcare in developing markets, noting that in some contexts "the outside option is basically receiving no healthcare."
A further session examined the enterprise landscape. "AI is fundamentally reshaping the enterprise landscape," one participant said. Rather than simply replacing jobs, the transformation is about "a race to technologise."
Discussion also turned to AI's implications for economics itself. Hemanth Asirvatham of OpenAI observed, "If we are to think that AI is some transformative economic technology, we should also think it is a transformative technology for the field of economics."
Participants suggested new research methods, such as using fine-tuned models to identify relationships in complex datasets or simulate human preferences in economic modelling.
The event concluded with a broader reflection on the limits of current models and the institutional structures needed to support AI's integration into society. Participants debated whether AI progress could hit a ceiling, how to define task boundaries, and what institutions are needed for a future shaped by AI agents.
As the forum closed, Chatterji left the group with a forward-looking message: "I hope you'll think of this as not sort of the end of a one-off event, but… the beginning of a journey that we're gonna be on together."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Otago Daily Times
4 days ago
- Otago Daily Times
Students shown area's opportunities
This year's South Canterbury Year 11 Pathways Expo was held at the Southern Trust Events Centre, attended by over 750 students from across the region. PHOTO: SUPPLIED More than 750 students attended the 2025 South Canterbury Year 11 Pathways Expo at the Southern Trust Events Centre this month. The annual career expo connected youth with local career options. The event offered year 11 students, from across the region, the chance to engage directly with more than 30 local businesses and training providers. Venture Timaru vocational co-ordinator Liam Brown said the event was structured around a mix of fast-paced speed networking sessions and a traditional expo format, allowing students to have meaningful, small-group conversations with industry professionals. The expo featured a lineup of six guest speakers, who shared their personal career journeys — offering real-world inspiration and advice. Mr Brown said the opening speaker Mayor Nigel Bowen "set the scene for the day" talking about the importance of using initiative, encouraging young people to approach businesses, seek shadowing opportunities and gain insight. "He highlighted the region's strong network of supportive businesses committed to fostering youth participation in the workforce." Mr Brown said feedback from businesses on the day was overwhelmingly positive, with many commenting on the engagement of the students and the value of the mixed format allowing direct connection. Mr Brown put down the enthusiasm of the attending business and their staff and the work career advisers do in prepping their students prior to the event. The expo was run in collaboration with by the My Next Move youth initiative, the local Careers and Transition Education group, and funded by Venture Timaru. He said the expo had become a cornerstone event for helping students explore vocational pathways and better understand the opportunities available within their own community. "With subject choices and career decisions looming, it's critical that young people engage with the world of work early, learning not just what jobs exist, but also what skills, qualifications and mindsets are needed to succeed. "Events like the Pathways Expo give year 11 students the chance to gain this insight first hand, allowing time to reflect on their options and make more informed decisions when it comes time to leave secondary school," he said. — APL


Scoop
4 days ago
- Scoop
Global Study: COVID-19 And Adenoviral Vaccines Tied To GBS Risk, Not MRNA Vaccines
Press Release – Global Vaccine Data Network GBS is a rare but serious neurological condition that can cause progressive limb weakness and eventual paralysis, with an annual incidence of 1 to 4 cases per 100,000 people worldwide. It has been linked to various infections, including Campylobacter … Large-scale study in a population covering more than 230 million people sheds light on the relationship between Guillain-Barré syndrome after COVID-19 vaccines or SARS-CoV-2 infection. Auckland, 29 May 2025 – A new multinational study analysing data from over 230 million people across 20 global sites highlights the relationship between SARS-CoV-2 infection, certain COVID-19 vaccines, and Guillain-Barré syndrome (GBS). This research reinforces the importance of continuous vaccine safety monitoring and highlights key differences in risk associated with different vaccine types. GBS is a rare but serious neurological condition that can cause progressive limb weakness and eventual paralysis, with an annual incidence of 1 to 4 cases per 100,000 people worldwide. It has been linked to various infections, including Campylobacter jejuni, Zika virus, influenza, and SARS-CoV-2. The study used advanced epidemiological methods and healthcare data from 20 sites within GVDN: seven sites from the African COVID-19 Vaccine Safety Surveillance (ACVaSS) system: Ethiopia, Ghana, Kenya, Malawi, Mali, Mozambique, and Nigeria; Argentina; New South Wales and Victoria in Australia; British Columbia and Ontario in Canada; Denmark; Finland; Indonesia; Republic of Korea; South Africa; and three Vaccine monitoring Collaboration for Europe (VAC4EU) sites: Catalonia and Valencia in Spain, and the United Kingdom. People infected with SARS-CoV-2 were around three times more likely to develop Guillain-Barré syndrome (GBS) within six weeks of infection compared to other times, suggesting that infection with this virus increases the risk of GBS. An increased risk was also observed following adenoviral vector vaccines (AstraZeneca, Janssen/Johnson & Johnson), but not after mRNA vaccines (Pfizer-BioNTech, Moderna) or inactivated vaccines (Coronavac/Sinovac). 'If you are concerned about the risk of rare but serious side effects of vaccines such as GBS, you should know that receiving an mRNA COVID-19 vaccine does not appear to increase your risk, but infection with the virus does,' said Dr. Jeff Kwong, senior author for the study based at ICES and the University of Toronto in Canada. 'This study reinforces what we have known for some time—the potential health risks from COVID-19 disease are greater than the risks following COVID-19 vaccination, which plays an important role in protecting us from serious risks posed by infection.' 'Understanding the relative risks of vaccination and infection is critical. This study reinforces that while certain vaccines may carry small risks, SARS-CoV-2 infection itself presents a much greater threat to neurological health,' said Dr. Sharifa Nasreen, Assistant Professor at SUNY Downstate Health Sciences University, USA. 'Our findings emphasise that vaccine safety is not static—it is continuously studied and evaluated. The global research community remains committed to ensuring public confidence through ongoing safety monitoring and evidence-based guidance,' said Dr. Helen Petousis-Harris, GVDN Co-Director and Associate Professor at the University of Auckland. GVDN collaborates with leading research institutions, policymakers, and vaccine organisations across six continents to create a comprehensive, evidence-based approach to vaccine safety and effectiveness. This large-scale study underscores the importance of vaccination as a tool for public health, not only in preventing severe disease but in reducing rare complications like GBS. Dr. Steve Black, GVDN Co-Director, stated, 'GVDN has long been committed to rigorous and transparent vaccine safety research. The size and diversity of this study population, attained through multinational collaboration, is a testament to this. Our findings highlight the importance of continuous monitoring and real-world data to guide public health decisions.' About Global Vaccine Data Network™ (GVDN®) Global Vaccine Data Network (GVDN) brings together researchers across six continents to deliver independent, real-world data on vaccine safety and effectiveness, supporting evidence-based public health decisions. Established in 2019, GVDN collaborates with renowned research institutions, policy-makers, and vaccine-related organisations to establish a harmonised and evidence-based approach to evaluating vaccine safety and effectiveness using data sourced from millions of individuals across six continents. GVDN is supported by the Global Coordinating Centre based at Auckland UniServices Limited, a not-for-profit, stand-alone company that provides support to researchers and is wholly owned by the Waipapa Taumata Rau, University of Auckland. Aiming to gain a comprehensive understanding of vaccine safety and effectiveness profiles, GVDN strives to create a safer immunisation landscape that empowers decision-making for the global community. For further information, visit Disclaimer This news release summarises the key findings of the GVDN study to identify the association between the risk of Guillain-Barré Syndrome (GBS) and COVID-19 infection or vaccination. To view the full publication in Vaccine, visit This project was supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS). The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, CDC/HHS, or the U.S. Government.


Scoop
4 days ago
- Scoop
Global Study: COVID-19 And Adenoviral Vaccines Tied To GBS Risk, Not MRNA Vaccines
Press Release – Global Vaccine Data Network GBS is a rare but serious neurological condition that can cause progressive limb weakness and eventual paralysis, with an annual incidence of 1 to 4 cases per 100,000 people worldwide. It has been linked to various infections, including Campylobacter … Large-scale study in a population covering more than 230 million people sheds light on the relationship between Guillain-Barré syndrome after COVID-19 vaccines or SARS-CoV-2 infection. Auckland, 29 May 2025 – A new multinational study analysing data from over 230 million people across 20 global sites highlights the relationship between SARS-CoV-2 infection, certain COVID-19 vaccines, and Guillain-Barré syndrome (GBS). This research reinforces the importance of continuous vaccine safety monitoring and highlights key differences in risk associated with different vaccine types. GBS is a rare but serious neurological condition that can cause progressive limb weakness and eventual paralysis, with an annual incidence of 1 to 4 cases per 100,000 people worldwide. It has been linked to various infections, including Campylobacter jejuni, Zika virus, influenza, and SARS-CoV-2. The study used advanced epidemiological methods and healthcare data from 20 sites within GVDN: seven sites from the African COVID-19 Vaccine Safety Surveillance (ACVaSS) system: Ethiopia, Ghana, Kenya, Malawi, Mali, Mozambique, and Nigeria; Argentina; New South Wales and Victoria in Australia; British Columbia and Ontario in Canada; Denmark; Finland; Indonesia; Republic of Korea; South Africa; and three Vaccine monitoring Collaboration for Europe (VAC4EU) sites: Catalonia and Valencia in Spain, and the United Kingdom. People infected with SARS-CoV-2 were around three times more likely to develop Guillain-Barré syndrome (GBS) within six weeks of infection compared to other times, suggesting that infection with this virus increases the risk of GBS. An increased risk was also observed following adenoviral vector vaccines (AstraZeneca, Janssen/Johnson & Johnson), but not after mRNA vaccines (Pfizer-BioNTech, Moderna) or inactivated vaccines (Coronavac/Sinovac). 'If you are concerned about the risk of rare but serious side effects of vaccines such as GBS, you should know that receiving an mRNA COVID-19 vaccine does not appear to increase your risk, but infection with the virus does,' said Dr. Jeff Kwong, senior author for the study based at ICES and the University of Toronto in Canada. 'This study reinforces what we have known for some time—the potential health risks from COVID-19 disease are greater than the risks following COVID-19 vaccination, which plays an important role in protecting us from serious risks posed by infection.' 'Understanding the relative risks of vaccination and infection is critical. This study reinforces that while certain vaccines may carry small risks, SARS-CoV-2 infection itself presents a much greater threat to neurological health,' said Dr. Sharifa Nasreen, Assistant Professor at SUNY Downstate Health Sciences University, USA. 'Our findings emphasise that vaccine safety is not static—it is continuously studied and evaluated. The global research community remains committed to ensuring public confidence through ongoing safety monitoring and evidence-based guidance,' said Dr. Helen Petousis-Harris, GVDN Co-Director and Associate Professor at the University of Auckland. GVDN collaborates with leading research institutions, policymakers, and vaccine organisations across six continents to create a comprehensive, evidence-based approach to vaccine safety and effectiveness. This large-scale study underscores the importance of vaccination as a tool for public health, not only in preventing severe disease but in reducing rare complications like GBS. Dr. Steve Black, GVDN Co-Director, stated, 'GVDN has long been committed to rigorous and transparent vaccine safety research. The size and diversity of this study population, attained through multinational collaboration, is a testament to this. Our findings highlight the importance of continuous monitoring and real-world data to guide public health decisions.' About Global Vaccine Data Network™ (GVDN®) Global Vaccine Data Network (GVDN) brings together researchers across six continents to deliver independent, real-world data on vaccine safety and effectiveness, supporting evidence-based public health decisions. Established in 2019, GVDN collaborates with renowned research institutions, policy-makers, and vaccine-related organisations to establish a harmonised and evidence-based approach to evaluating vaccine safety and effectiveness using data sourced from millions of individuals across six continents. GVDN is supported by the Global Coordinating Centre based at Auckland UniServices Limited, a not-for-profit, stand-alone company that provides support to researchers and is wholly owned by the Waipapa Taumata Rau, University of Auckland. Aiming to gain a comprehensive understanding of vaccine safety and effectiveness profiles, GVDN strives to create a safer immunisation landscape that empowers decision-making for the global community. For further information, visit Disclaimer This news release summarises the key findings of the GVDN study to identify the association between the risk of Guillain-Barré Syndrome (GBS) and COVID-19 infection or vaccination. To view the full publication in Vaccine, visit This project was supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS). The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, CDC/HHS, or the U.S. Government.